Dear Fellow Skeptic,

You and I both know that investing services often make promises they can’t keep.

Every time I see an ad that has crazy claims of instant riches, I can’t help but think to myself…

“If they’re so good, why don’t they let people try their service first – before having to pay for it?” 

The answer is simple: Few investors can live up to the marketing hype. 

The fact is, if they got paid based solely on their investment performance, most of them would be dead broke.

But still, paying upfront before you know if a trader is any good isn’t even the worst part … 

… The worst part is that you could lose thousands of dollars - just to find out!!

A Large Gap Between the Value of a Company and What the Common Stock is Selling for 

Ok, so ingredient #1 is a large gap between the value of a company and what the common stock is selling for.

Let me repeat that---the first ingredient you need is a large gap between the value of the company and what the common stock is selling for.

Some of you reading this may recall that we recommended Array Biopharma originally at $18.90 a share.

Now Array stock was selling for $18.90. But we believed the company was worth close to $50 a share.

And this is something I need everyone reading right now to understand.

There’s a big difference between the value of a business and what the common stock is selling for.

That’s why when a deal was announced, we made 148% in one morning with Array!

You Need a Board of Directors Open to a Legitimate Offer.

Ok, we originally recommended Loxo Oncology at $131 a share on Friday, January 4th of 2019.

Now Loxo had a board of directors that were open to a deal.

The CEO of Loxo was a healthcare banker on Wall Street. The COO came from Goldman Sachs.

Basically, these guys were born and bred to do deals. That’s what they do. That’s why…

You Need Potential Buyers.

We recommended Tesaro stock $38 on October 1st, 2018. And it was taken over by Glaxo 63 days later for 91% gain.

Just like today’s company, Tesaro also developed a platform treatment. It too was for cancer.

And that got Big Pharma’s attention. They believed this new platform would treat not just one form of cancer but several.

Glaxo snagged them first. 

Once again, what you’re looking at right now is an illustration of this company’s breakthrough cancer platform ---

What makes it so exciting is that it uses a patient’s own fighter T-cells to attack solid tumors.

This causes tumors to shrink and die.

It was first discovered by an American scientist who’s been called “the father of cancer immunotherapy.”

He and his team were trying to find a new way to attack melanoma.

Something that uses our own body's natural defenses against solid tumors.

Now all of you have heard of Chemotherapy. Maybe you know a loved one who has had to go through it. I know I have.

Well right now the most popular drug for people diagnosed with melanoma is called Dacarbazine.

Now Dacarbazine, was approved for medical use in 1975.

That’s 45 years ago!

Think about that for a moment…

And 45 years ago, they didn’t know anything about cancer’s DNA.

Dacarbazine is a chemical drug based on one-size-fits-all basic human chemistry.

And, as anyone who’s gone through chemo knows, chemical drugs have two awful problems-- (1) they’re hit-or-miss; (2) they have terrible side effects.

For example, the common side effects for Dacarbazine include vomiting, loss of appetite, liver problems and other allergic reactions.

Come on. Most of you here with us today know what I’m talking about. Going through chemo or watching a loved one go through it is brutal. Absolutely brutal.

This is what they mean by the expression “the chemo will get you before the cancer does.” 

Chemical drugs like Dacarbazine are the “OLD WAY” of doing things.

An approach that took advantage of what they just learned when the unlocked the human genome…

They wanted to invent treatments based on someone’s actual genetic profile….

Because the old way of doing things is just to prescribe each of them a drug like Dacarbazine.

They’d all get the same drug, regardless of personal profile.

But now we can profile both the DNA of the patient and that of the specific cancer they have…

…and prescribe drugs based on those specific profiles!

And today’s company does just that.

How?

That’s what we call a platform technology.

Instead of inventing one drug to treat one disease, they’ve invented one drug to treat multiple diseases…

The fact that this breakthrough is proving to be so effective at doing this is why this is such a game-changer.

That’s because right now there’s a war being fought inside of your medicine cabinet. It’s a war being fought over people with cancer.

And the war is being fought by the biggest pharmaceutical companies in the world. They’re fighting each other over shelf space.

Why?

Because it’s very expensive to treat cancer. I know this from first-hand experience.

The average cost for chemotherapy drugs alone is $13,176 a month.

That comes out to $158,112 a year.

Unbelievable really.

But that’s how Big Pharma sees it: someone with cancer is worth, on average, $158,000 a year.

1.7 million people are diagnosed with cancer each year in the United States. This is big business. Very big business.

That’s why these companies are fighting so hard for a piece of your medicine cabinet.

As I mentioned, the company just won FDA approval on its melanoma drug.

Now there are 1.6 million people diagnosed with solid tumors each year.

Assume that each patient is worth, on average, $158,000 a year.

That makes it a $252 billion market.

But remember, this is a platform technology. It gives Big Pharma a bigger slice of the medicine cabinet.

That’s why Big Pharma has just spent $100 billion buying competitors with similar platforms.

Big Pharma thinks it can be used to treat a variety of other diseases. And forgive me for being so crude, but those are the big markets.

According to Research and Markets, the solid tumor cancer market alone is expected to hit $424 billion in 2027.

That’s why Big Pharma is so interested.

There’s big money here.

And this is why we see a deal happening so quickly.

You see, there a bunch of drug companies that are waging a war to get their medicines on the shelves of cancer patients.

As you can see from the graphic here, this is the list of the top 10 cancer drug companies in the world…

Now Eli Lilly bought out Loxo Oncology, which we recommended, for their own cancer platform technology.

And Glaxo bought out Tesaro, which we recommended, for their own cancer platform technology.

And Pfizer bought out Array Biopharma, which we recommended, for their own cancer platform technology.

In my view, that leaves Astra Zeneca or Bristol Meyers as the most likely buyers. That's despite the fact that the company has reportedly held talks with Gilead and Takeda.

I think the most likely buyer is Astra Zeneca. They already have a partnership with our target company.

But whoever the final buyer turns out to be the deal will likely look at the potential size of the opportunity.

And that’s how we made a fast 72% profit with Pacific Biosciences.

Remember, the entire solid tumor market is expected to be $424 billion by 2027.

If this company only treats the 10% of the market, their slice of it could be as high as $40 billion a year.

But let’s cut that even further.

If this company just wins 1/3 of that market, we’re looking at $12 billion in drug sales a year.

Oncology-focused biotech companies go for 2 – 3 times expected future pipeline sales.

At 2 times expected sales that’s a $24 billion deal.

At 3 times sales its a $36 billion deal.

Chances are it’s right in the middle.

Now I want everyone to pay attention right now because we’re about to go over something really important...so look, first and foremost, let me say this:

When it comes to takeovers, there’s always a risk that things don’t go as planned.

But let me tell you why I think this stock is a great buy whether or not a deal happens.

But this drug is so powerful the company signed a big deal with Astra Zeneca.

And that’s just for melanoma. That doesn’t include the other drugs their platform could be used for.

In other words, this is NOT two guys in a lab testing mice.

Top management has a proven management team with experience at many of the biggest drug companies on earth - including Bristol-Myers, Roche and Johnson & Johnson.

In other words, this is a proven team who’s already created billions of shareholder value in the exact same industry that this company operates in.

That’s why we believe that a deal could be announced any day…

So to sum it all up…  

Sure, any takeover target could not go through as planned…  

But look at what this company has in place already -

These guys know what it takes to win.

We feel good about this company.

Now let’s look at everything we just discussed in the context of what we talked about in the beginning of today's presentation.

Remember, we said that when we’re looking for takeover targets, we have to make sure the target has 3 things in place -

• A Large Gap Between the value of the company and what the common stock is actually selling for
• A board of directors open to a legitimate offer
• You need potential buyers.

Now let’s take these one at a time.

Ingredient #1 - A Large Gap Between the value of the company and what the common stock is actually selling For.

Remember what we said: oncology-focused biotech companies go for 2 – 3 times expected future pipeline sales.

With sales expected to be $12 billion a year we’re looking at a deal that is 2 to 3 times the value of the entire company today.

We see a deal at 3 times the price of the stock today.

That would hand investors a profit of 625 - 800% (or more) based on how we recommend playing it.

At the low end of the range, you could see a 300% return. At the high end of the range, you could see a 700% return.

Chances are it’s somewhere in the middle.

Ok onto ingredient #2...

Ingredient #2: A Board of Directors Open to a Legitimate Offer

Remember, the CEO of this company just sold another biotech to AstraZeneca.

And she’s begun surrounding herself with a senior management team of people with similar experience.

So, she knows how to build companies and she knows how to sell them. She’s a deal maker.

And finally, you need ingredient #3: potential buyers.

As I mentioned earlier, AstraZeneca is the most logical buyer.

Those two companies are the only ones who haven’t found a dance partner with these new drugs in the melanoma segment. And I think AstraZeneca is the most likely buyer.

But as we mentioned earlier, while I believe you can see a 525% return, things don’t always go as planned. That’s not the way the world works…

So even if a deal doesn’t happen, the company’s drug pipeline will likely cause this company’s value to soar over the next 3 years…

This path could conservatively hand early investors like you 600% (or more) on your money.

It’ll just take longer.

But look folks I’ve been picking takeovers for 30 years. Some of my Wall Street clients helped me bankroll my brokerage firm Lexington Capital Partners.

In the past 24 months, we’ve owned many stocks that were taken over.

Only two of those four times was the chance of a deal so high.

One was with American Railcar!

Just like today’s company, Greenbrier didn’t have much of a choice. They had to make a deal to buy the company and they had to do it fast.

If Greenbrier didn’t buy American Railcar, Burlington Northern could have seriously threatened Greenbrier’s business.

We made 51% gains when the deal was announced for $69.93.

Ok, and moving on, the last time I saw an opportunity like this was when Glaxo bought Tesaro in October 2018.

I mean Glaxo hired a new chief scientific officer who publicly said they wanted to invest in oncology treatments that attack cancer at its DNA level.

There were only three companies that did that. But everything was pointing to Tesaro. Within 63 days of recommending it, the company was acquired.

Takeover Targets is unlike any other service you’ve ever subscribed to before…

For one thing, we only publish research and recommendations around takeovers… opportunities like the one we’ve been telling you about today.

Which also means that this service is unique because it’ll give you the chance to earn much higher returns and much faster than average investments.  

Again, as you’ve learned today, the reason most folks come up short in their investing is simple - they’ve been investing in the wrong places!  

Average investment strategies give you average investment returns.  

But by knowing how to invest in takeovers, you’ll give yourself the chance to earn potentially life-changing profits each and every month.  

And when you become a member of Takeover Targets today, you’ll get that chance again and again...  

That’s because after you join today and download “Our #1 Takeover Target this Month”, we’ll send you a new pick every single week.  

Over the next year, you’ll receive as many as 48 takeover targets— ideas that could multiply your wealth many times over.  

I don’t recommend anything unless you can double your money on it. Why would it? It’s a waste of time.

Now I know that some of the numbers we’re tossing around here — numbers like 625% your money or 800% on your money — they may sound hard to believe.

But here’s the thing...

I’ve been picking takeovers since 1992.

My clients invested the profits I made them into my brokerage firm.

So you’re not letting a rookie take you on a wild-goose chase.

Picking takeover targets is what I do…

That’s why we’ve recommended so many successful takeovers in the past three years. That’s one every 24 days, on average!

Now to be clear, most of these stocks weren’t on anybody else’s radar – but some good old-fashioned homework on my part brought my customers gains of 73%, 93% and even 148% – in as little as 4 days.

We’ve already helped hundreds of investors just like you...

But now it’s your turn. 

Let me help you build a portfolio of solid takeover targets ... Investments just like the one we’ve been telling you about today.  

Again, after you join Takeover Targets, you’re going to begin receiving a new target each and every month…  

It won’t be long before you’re well on your way to building a diversified portfolio of high-quality — and hopefully, highly-profitable — takeover targets  

And don’t forget, we’ve already helped hundreds of investors just like you do the exact same thing...

And as a Takeover Targets member, we’ll try to find the same types of deals for you every month...

In fact, we believe that the company we’ve been telling you about today could become our most profitable takeover target this year.

Again, at the low-end of the range, you stand to earn a 625% return...

But at the high-end, your profits could reach 800%... and possibly far more.

It’s also worth mentioning that we have no incentive to try and “sell” you on making this investment...

We’re not acting as this company’s banker or broker, and it’s not compensating us in any way.

Behind the Markets is an independent provider of investment research. We don’t accept any compensation from the companies we write research on.

And I’m just telling you about a stock I believe is going to be acquired as soon as this month. 

Let me quickly recap what you can expect to get as a member of Takeover Targets:

• Unmatched Advice, Winning Recommendations: You’ll get the benefit of the best investment experience money can buy in 48 weekly issues (due to holidays) of Takeover Targets – e-mailed to your inbox every Friday. Once you get the email, simply call your broker or place your trade online. Value: $1,497

• FREE Bonus #1: “Our #1 Biotech Takeover Target for September”: This in-depth report will give you all the details on the amazing biotech company we just discussed in our presentation – and why we think it offers you a 525% return opportunity! Value: $1,497

• FREE Bonus #2: My "Key Code" System: How to Skim Extra Money Each Month from Takeovers: This rare presentation offers you an inside look at the technique I’ve used to pick so many takeover targets during the past thirty years! Value: $997

• 100% Money-Back Guarantee: Because I want you to profit from my advice without fear and without hesitation, I’m backing up my claims with an unconditional guarantee: Try Takeover Targets risk free. If you don’t like the service in the first 30 days for any reason whatsoever, every dime you paid toward your membership will be returned to you. The reports are yours to keep.

Whatever you do, don’t forget that, with your free bonus reports, you’ll immediately get…

I’m serious about starting this relationship off on the right foot.

And while I’m 100% confident that I can help you become much richer through the specific, fast-paced, high profit recommendations I’ll be emailing you each week …

… Even if you don’t like the service, you’ll still have the free reports to keep – and the 6 trades that can bring you huge profits immediately.

And don’t forget, sometimes I like to trade very quickly – that means profits can happen very quickly as well.

You have to act fast if you want to make profits like the 72% with Pacific Biosciences…

Or the 71% gain taken from the trades we made with Loxo Oncology…

But most importantly, don’t miss this opportunity to get on board for much less than anyone will ever get it for again.

My point is, now is not the time to delay.

This is truly a trader’s market – one that will kill the uninitiated at the expense of the big-money professionals. With this kind of volatility, there’s an endless supply of money making-ideas opportunities being left on the table every day that a seasoned pro like myself is more than willing to pick up.

Not only can you make good profits, but the profits come fast and furious at times like these.

Most other services don’t have membership limits. Those that do – usually the ones that only deal in thinly traded options – typically accept 5,000 people or so, because they don’t want too many people chasing the same trades and “moving the market.”

But I’ve insisted that we limit our total membership to only 500 people. And I’ve made this request for a much different reason than you might imagine … actually, two reasons:

First, as a brokerage firm owner for a small group of ultra-high net worth individuals, I’ve gotten used to moving quickly and quietly through different markets around the world.

And that’s an advantage I absolutely refuse to risk losing. If I allow too many people into this service … and am no longer able to move around the market “below the radar” … I fear I wouldn’t be able to deliver at the level you expect of me.

The second reason for this very strict limit on memberships is more personal.

When I first started my career on Wall Street, I couldn’t imagine anything being more important to my job satisfaction than the bottom line. I figured that the more money I made, the happier and more successful I’d be.

Now that I’m a bit older and quite a bit wiser, I’ve realized that there’s something that I value even more than the jingle-jangle of change in my pocket:

The feeling of family that’s developed between me and the people who trust me with their investments. It’s a huge responsibility, and one that I’ve been able to live up to. And I gotta tell you, it really hits home around the holidays when my clients and I exchange gifts.

This is the kind of feeling that I want to shoot for in Takeover Targets…

So, in short, that’s why I’m urging you to take advantage of this risk-free offer right now.

Your free special reports will follow in your inbox immediately.

I look forward to working for you and making money together.

Will you join me?

Click here and we’ll get started.

“The Buck Stops Here,”